This is a first-in-human (FIH) Phase I/II, multi-center, open-label, study of ANS02, in patients with advanced NSCLC. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS02 as monotherapy.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
294
4 dose levels would be explored during the study.
Research Site
Fairfax, Virginia, United States
RECRUITINGResearch Site
Guangzhou, Guangdong, China
NOT_YET_RECRUITINGResearch Site
Harbin, Heilongjiang, China
RECRUITINGIncidence of Adverse Events (AEs)
Number of patients with adverse events by system organ class and preferred term
Time frame: From the time of first dose to 28 days post last dose of ANS02
Incidence of Serious Adverse Events (SAEs)
Number of patients with serious adverse events by system organ class and preferred term
Time frame: From time of first dose to 28 days post last dose of ANS02
Incidence of dose-limiting toxicities (DLT) as defined in the protocol
Number of patients with at least 1 dose-limiting toxicity (DLT), which is any toxicity defined as a DLT in the Clinical Study Protocol
Time frame: From time of first dose of ANS02 to end of DLT period (approximately 28 days)
Incidence of baseline laboratory finding, ECG and vital signs changes
Measured by laboratory and vital sign variables over time including change from baseline
Time frame: From time of first dose to 28 days post last dose of ANS02
Pharmacokinetics of ANS02: Plasma PK concentrations
Measurement of plasma concentrations of ANS02
Time frame: From date of first dose of ANS02 up until 7 days post last dose
Pharmacokinetics of ANS02: Area under the concentration time curve (AUC)
Measurement of PK parameters: Area under the concentration time curve (AUC)
Time frame: From date of first dose of ANS2 up until 7 days post last dose
Pharmacokinetics of ANS02: Maximum plasma concentration of the study drug (C-max)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
Zhengzhou, Henan, China
NOT_YET_RECRUITINGStudy Site
Chengdu, Sichuan, China
NOT_YET_RECRUITINGMeasurement of PK parameters: Maximum observed plasma concentration of the study drug (C-max)
Time frame: From date of first dose up until 7 days post last dose
Pharmacokinetics of ANS02: Time to maximum plasma concentration of the study drug (T-max)
Measurement of PK parameters: Time to maximum observed plasma concentration of the study drug (T-max)
Time frame: From date of first dose up until 7 days post last dose
Pharmacokinetics of ANS02: Clearance
Measurement of PK parameters: the volume of plasma from which the study drug is completely removed per unit time (Clearance)
Time frame: From date of first dose up until 7 days post last dose
Pharmacokinetics of ANS02: Half-life
Measurement of PK parameters: Terminal elimination half-life (t 1/2)
Time frame: From date of first dose up until 7 days post last dose
Proportion of patients with radiological response (ORR)
Assessed by overall response rate (ORR) defined as the proportion of patients who have a confirmed complete or partial radiological response by the Investigator according to RECIST v1.1
Time frame: From date of first dose of ANS02 until progression, or the last evaluable assessment in the absence of progression （approximately 2 years)
Duration of Response (DoR)
The time from date of first response until date of disease progression or last evaluable assessment (RECIST v1.1) in the absence of progression
Time frame: From date of first dose of ANS02 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years)
Disease Control Rate (DCR)
The percentage of patients with confirmed CR or PR or having SD maintained (RECIST v1.1)
Time frame: From date of first dose of ANS02 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years)
Progression free Survival (PFS)
The time from first dose until RECIST 1.1 defined disease progression or death due to any cause
Time frame: From date of first dose of ANS02 up until date of progression or death due to any cause (approximately 2 years)]
Overall Survival (OS)
The time from the date of the first dose of study treatment until death due to any cause
Time frame: From date of first dose of ANS02 up until the date of death due to any cause (approximately 2 years)